GT Biopharma GTBP Stock News

GT Biopharma (OTCMKTS: GTBP) has set the foundation for strong growth ahead. The company announced that it has completed a private offering, even in the midst of the COVID-19 pandemic. Moreover, as the company sets up for a major uplisting, the stock deserves your attention. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GTBP Raises $5.6 Million To Continue Work On Its Clinical Trial

In the press release, GT Biopharma announced that it completed a private offering. Through the offering, the company raised gross proceeds in the amount of $5.6 million. The funds were raised in order for the company to continue the development of a potential AML treatment. 

At the moment, GTBP is conducting a Phase I/II clinical trial for GTB-3550 at the Masonic Cancer Center. The treatment is a tri-specific recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and modified form of IL-15. 

Not only is the company assessing its technology as a potential AML, or Acute Myeloid Leukemia treatment, it is also assessing it as a potential treatment in COVID-19. This aggressive form of cancer has a high mortality rate. However, GTB-3550 has shown some early promise in the treatment of this devastating cancer. 

In a statement, Anthony Cataldo, Chairman and CEO at GTBP, had the following to offer:

“We are pleased to have completed our bridge financing which allows us to continue to fund our FDA clinical trial and helps to position the company to seek approval for listing on a national securities exchange. We are pleased with the progress our clinical development team is making with the evaluation of GTB-3550 in AML advanced cancer patients and will be providing further clinical updates to our stakeholders in the coming weeks.”

This News Is Huge

The news released by GTBP this morning is a huge step in the right direction for the company. First and foremost, the ability of a company with such a small market cap to raise $5.6 million in a COVID-19-riddled environment is impressive in and of itself. However, there’s a bit more to this release. 

The company now has the funding it needs to continue work in not only AML, an incredibly high-value indication with significant unmet need. 

Moreover, in Mr. Cataldo’s statement, he mentioned work to uplist to a major stock exchange. This could lead to stronger investor interest and incredible liquidity. All in all, investors should pay close attention to GTBP. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Get Free Alerts

Join our free mailing list to receive stock alerts!

This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and GT Biopharma, CNA Finance has been hired for a period beginning on 3/1/20 and ending on 4/31/20 to conduct digital advertising and marketing and publicly disseminate information about GTBP via Websites and Email. We have an agreement and have been paid fifteen thousand dollars via bank wire transfer to cover the cost of content production. The agreement was extended on May 25 and will run through June 24, 2020. For this extension, GTBP paid CNA Finance an additional fifteen thousand dollars. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and GT Biopharma has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.